富马酸地洛昔梅尔- MS代理的新转变畅销书

IF 1.3 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2022-07-01 DOI:10.1002/pnp.752

T. Gaber

{"title":"富马酸地洛昔梅尔- MS代理的新转变畅销书","authors":"T. Gaber","doi":"10.1002/pnp.752","DOIUrl":null,"url":null,"abstract":"Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 NICE used FTA to recommend diroximel fumarate (Vumerity) for the management of relapsing remitting multiple sclerosis (RRMS). This short article explores the potential role the drug may play within the pantheon of disease modifying treatment for RRMS.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diroximel fumarate – a new twist for MS agent best seller\",\"authors\":\"T. Gaber\",\"doi\":\"10.1002/pnp.752\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 NICE used FTA to recommend diroximel fumarate (Vumerity) for the management of relapsing remitting multiple sclerosis (RRMS). This short article explores the potential role the drug may play within the pantheon of disease modifying treatment for RRMS.\",\"PeriodicalId\":43913,\"journal\":{\"name\":\"Progress in Neurology and Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neurology and Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pnp.752\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neurology and Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pnp.752","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

NICE于2017年采用了快速通道评估（FTA）。这种更快、更简化的过程主要用于新型药物，这些药物被认为与已经推荐的药物具有生物等效性，具有额外的优势或降低了成本。2022年6月，NICE使用FTA推荐富马酸二肟（Vumerity）用于复发缓解型多发性硬化症（RRMS）的治疗。这篇短文探讨了该药物在RRMS疾病改良治疗中可能发挥的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Diroximel fumarate – a new twist for MS agent best seller

Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 NICE used FTA to recommend diroximel fumarate (Vumerity) for the management of relapsing remitting multiple sclerosis (RRMS). This short article explores the potential role the drug may play within the pantheon of disease modifying treatment for RRMS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.